Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulcrum Therapeutics reports promising data and financial stability in Q4

Fulcrum Therapeutics showcased positive data for FTX-6058 and financial stability in their Q4 2022 earnings call
While facing challenges with the clinical hold, the company's strong cash position and promising programs offer opportunities for growth

Fulcrum Therapeutics reports solid financials, FDA challenges, and leadership change

Fulcrum Therapeutics navigates a mixed landscape with strong financials, promising clinical trial progress, and regulatory challenges that require careful resolution.
New leadership, ongoing FDA collaborations, and a robust cash position position Fulcrum for continued growth and innovation in the biopharmaceutical space.

Fulcrum Therapeutics reports stable finances, regulatory hurdles ahead

Fulcrum Therapeutics maintains a stable financial position with a focus on advancing key pipeline candidates.
Challenges include regulatory uncertainties for FTX-6058 and ongoing R&D investment impacting financials.
Opportunities lie in upcoming data releases, resolving regulatory issues, and strategic growth initiatives.

Fulcrum Therapeutics reports Q3 loss, progresses key clinical trials

Fulcrum Therapeutics reported a mixed performance in Q3 2023, with a net loss driven by significant R&D and administrative expenses.
Despite challenges in cash burn and timeline for commercialization, the company's strong cash position and promising clinical developments highlight its potential.
Opportunities lie in advancing regulatory filings, leveraging positive clinical results, and exploring additional endpoints to showcase therapy efficacy.

Fulcrum Therapeutics advances Phase III trials, secures strong financial position

Fulcrum Therapeutics made significant progress in advancing its pipeline with successful trial enrollments and resolution of clinical holds.
Financially, the company ended 2023 on a strong note with a healthy cash position and reported financials.
Challenges lie in meeting trial endpoints and managing expenses, but opportunities exist in market reception and further data collection.
Overall, Fulcrum's proactive approach to clinical development and stakeholder engagement positions it well for future growth.

Fulcrum Therapeutics secures Sanofi collaboration, advances Phase III trials

Fulcrum Therapeutics' collaboration with Sanofi and strong financial position provide a solid foundation for future growth and development.
The company's focus on advancing Phase III trials, addressing unmet medical needs, and driving innovation through novel endpoints positions it well for success.
While facing challenges in various operational aspects, Fulcrum's strategic planning and emphasis on key appointments and market access strategies indicate a proactive approach to overcoming obstacles.

Fulcrum Therapeutics reports strong Q2 earnings and advances clinical assets

Fulcrum Therapeutics achieved a significant turnaround in financial performance with a notable increase in net income and a strong cash position, supported by collaboration revenue.
Progress in Phase III trials for losmapimod and pociredir, along with positive patient engagement, bodes well for future drug development and market potential.
While facing regulatory and competitive challenges, the company's strategic collaborations, financial stability, and ongoing trials present opportunities for growth and market expansion.

Fulcrum Therapeutics navigates workforce reduction, focuses on sickle cell treatment

Fulcrum Therapeutics faces challenges with workforce reduction and program suspension but remains focused on advancing pociredir for sickle cell disease treatment.
The company's financial position is strong, with a cash balance of $257.2 million and plans to manage cash burn effectively in 2025.
Management changes and analyst inquiries underscore the need for strategic decision-making and operational efficiency to drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Financial Officer Iain Fraser - Senior Vice President, Early Development Patrick Horn - Chief Medical Officer Conference Call Participants Matthew Biegler - Oppenheimer Dae Gon Ha - Stifel Edward Tenthoff - Piper Sandler Rick Miller - Cantor Fitzgerald Greg Renza - RBC Capital Joori Park - Leerink Corinne Johnson - Goldman Sachs Operator Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel Healthcare Conference in New York City on November 19th at 3:35 pm ET. Management will also participate in one-on-one investor meetings.

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Deckers Outdoor

Gold Fields Ltd.

Grupo Financiero Galicia SA

New Gold

GGAL, GFI, FULC, DECK and NGD have been added to the Zacks Rank #1 (Strong Buy) List on November 12, 2024.

New Strong Buy Stocks for November 12th

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2024 financial results will be released on Wednesday, November 13, 2024, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

FULC is expected to provide updates on its early-stage candidate for SCD, pociredir, in its third-quarter earnings release.

Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

Fulcrum Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - FULC

CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - FULC

Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

An Investigation Has Commenced on Behalf of Fulcrum Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your FULC Losses

On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 3,605,932 shares in Fulcrum Therapeutics Inc (FULC, Financial), a clinical-stage biopharmaceutical company. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company to 1,724,014 shares, marking a notable shift in its investment strategy.

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Fulcrum Therapeutics, Inc. (FULC) Regarding Possible Securities Fraud Violations

Fulcrum Therapeutics (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround

LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

Fulcrum Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – FULC

LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

Fulcrum Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Fulcrum Therapeutics, Inc. (FULC)

LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.

Levi & Korsinsky Reminds Fulcrum Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - FULC

LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Fulcrum Therapeutics, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Invites Shareholders With Losses To Help

LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Fulcrum Therapeutics Inc Stock (FULC)